Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
| ▸ | PARP2 | Q9UGN5 | 9/20 | 1.00 |
| ▸ | PARP3 | Q9Y6F1 | 9/20 | 1.00 |
| ▸ | TNKS | O95271 | 1/20 | 1.00 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22022388 | 1.00 | PARP1 (1.00) | PARP1PARP2PARP3TNKSPARP6 | |
| SCHEMBL17941334 | 0.82 | PARP1 (0.74) | PARP1PARP2PARP3TNKSPARP6 | |
| SCHEMBL1824686 | 0.79 | PARP1 (0.86) | PARP1 | |
| SCHEMBL1689488 | 0.78 | PARP1 (1.00) | PARP1 | |
| SCHEMBL30415984 | 0.78 | PARP1 (1.00) | PARP1 | |
| SCHEMBL1689348 | 0.78 | PARP1 (0.86) | PARP1 | |
| SCHEMBL14125676 | 0.77 | PARP1 (0.64) | PARP1PARP2PARP3TNKSPARP6 | |
| SCHEMBL19569946 | 0.77 | PARP1 (0.93) | PARP1PARP2PARP3TNKSPARP6 | |
| SCHEMBL15918004 | 0.77 | PARP1 (0.64) | PARP1PARP2PARP3TNKSPARP6 | |
| SCHEMBL10053954 | 0.77 | PARP1 (0.72) | PARP1PARP2PARP3TNKSPARP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115285-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | TORAY INDUSTRIES, INC. (JP) | 2026-04-30 | — | — | US | disclosed |
| EP-4582101-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | Toray Industries, Inc. (JP) | 2025-07-09 | — | — | EP | disclosed |
| US-20250127907-A1 | PARP INHIBITORS | Stablix, Inc. | 2025-04-24 | — | — | US | disclosed |
| US-20250108213-A1 | COMPOSITIONS AND METHODS FOR ENHANCING THE EFFECT OF PLATINUM-BASED SYSTEMIC THERAPY | NOVOCURE GMBH (CH) | 2025-04-03 | — | — | US | disclosed |
| WO-2025068969-A1 | COMPOSITIONS AND METHODS FOR ENHANCING THE EFFECT OF PLATINUM-BASED SYSTEMIC THERAPY | NOVOCURE GMBH (CH) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024264072-A2 | PARP INHIBITORS | Stablix, Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024048542-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | 東レ株式会社 | 2024-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115285-A1 | MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER | PARP11, PARP1, PARP14 | PARP1 2/4885PARP2 5/4885PARP3 10/4885 |
| US-20250127907-A1 | PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885PARP2 2/4885PARP3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.